-
Report details
-
6
Figures
-
5
Tables
-
Market Analysis: Reimbursement
-
Overview of IVD Reimbursement
-
Outlook: Reimbursement
-
Executive News Briefing
-
Briefings
-
Kiffik Biomedical Closes Series A Financing
-
NeoGenomics Appoints Jack Kenny to Board of Directors
-
Cardio Diagnostics Launches Precision CHD Test in India
-
Cyclomics Closes €2.5 Million Investment Round
-
Truvian Appoints New Chief Medical and Strategy Officer
-
Alamar Biosciences Closes $50 Million in New Capital
-
Alamar Biosciences Welcomes New CSO
-
Hummingbird Diagnostics Appoints New CEO
-
Precede Biosciences Nabs $83.5 Million in Total Financing
-
Financial Highlights
-
Agilent Full Year Fiscal 2025 Sales up 7% in Business YOY
-
Mergers and Acquisitions
-
Partnerships and Collaborations
-
Industry Watch
-
Industry Watch COVID-19/Flu Update
-
Region Watch
-
Broad-based Company Announcements
-
Announcements
-
Mira Precision Health Launches ToxNav in U.S.
-
Beckton Dickinson Receives FDA Clearance and CE Marking
-
QuidelOrtho Captures FDA Clearance or VITROS Immunodiagnostic
-
FDA Proposes Reclassification of Companion Diagnostic Assays
-
Congress Discusses PAMA
-
MeMed Accelerates AI-enabled Acute-Care Diagnostics
-
Truvian Health Snags Clearance for Nine Additional Analytes
|
In Vitro Diagnostics Business Outlook, Volume 5, Issue 1 - Focus on Reimbursement
29 Jan 2026
The in vitro diagnostics (IVD) industry is a cornerstone of modern healthcare, empowering clinicians to detect disease, monitor health conditions, and guide treatment decisions with precision. As healthcare continues to evolve—driven by rising rates of chronic conditions such as diabetes and cardiovascular disease, along with ongoing and emerging infectious threats—the IVD market is undergoing constant change and growth.
In Vitro Diagnostics Business Outlook is a monthly intelligence publication designed to help industry professionals stay current in this fast-moving environment. Delivered in 12 issues annually, each issue focuses on a different segment of the IVD industry, providing timely insights, exclusive data, and in-depth analysis.
Featured Content
Each monthly issue provides:
-
Market Data and Forecasts
Detailed growth rates, market size, and market share to help identify emerging opportunities.
-
Comprehensive Market View
Coverage of key test categories and profiles of active companies across the IVD landscape.
-
M&A Activity Tracking
Updates on mergers, acquisitions, partnerships, and collaborations shaping the market.
-
Industry & Region Watch
Analysis of regional and segment-specific trends to support tailored strategic planning.
-
In-Depth News Analysis
Reporting on significant developments and events, including exclusive information not readily available elsewhere.
2026 Editorial Focus
Topics vary month to month, reflecting evolving industry priorities. In 2026, subscribers can expect issues dedicated to:
-
Reimbursement trends
-
Quality control reagents
-
Cardiac markers
-
STI point-of-care testing
-
Non-respiratory infectious diseases
-
An overall IVD market trend analysis
-
A forward-looking forecast of the respiratory testing market through 2027
- And more!
By delivering focused, actionable intelligence directly to subscribers’ each month, In Vitro Diagnostics Business Outlook helps decision-makers anticipate market shifts, identify growth opportunities, and navigate the complexities of the
Page Count: 30
Table of Contents
-
Market Analysis: Reimbursement
-
Overview of IVD Reimbursement
-
Outlook: Reimbursement
-
Executive News Briefing
-
Briefings
-
Kiffik Biomedical Closes Series A Financing
-
NeoGenomics Appoints Jack Kenny to Board of Directors
-
Cardio Diagnostics Launches Precision CHD Test in India
-
Cyclomics Closes €2.5 Million Investment Round
-
Truvian Appoints New Chief Medical and Strategy Officer
-
Alamar Biosciences Closes $50 Million in New Capital
-
Alamar Biosciences Welcomes New CSO
-
Hummingbird Diagnostics Appoints New CEO
-
Precede Biosciences Nabs $83.5 Million in Total Financing
-
Financial Highlights
-
Agilent Full Year Fiscal 2025 Sales up 7% in Business YOY
-
Mergers and Acquisitions
-
Partnerships and Collaborations
-
Industry Watch
-
Industry Watch COVID-19/Flu Update
-
Region Watch
-
Broad-based Company Announcements
-
Announcements
-
Mira Precision Health Launches ToxNav in U.S.
-
Beckton Dickinson Receives FDA Clearance and CE Marking
-
QuidelOrtho Captures FDA Clearance or VITROS Immunodiagnostic
-
FDA Proposes Reclassification of Companion Diagnostic Assays
-
Congress Discusses PAMA
-
MeMed Accelerates AI-enabled Acute-Care Diagnostics
-
Truvian Health Snags Clearance for Nine Additional Analytes
|
More information about this product
|